-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, AKiEGx0TnpOsVUCbjCNkwbGTm7m7DicdGEmL/hDE0ekphWJNPqH3gmqC02t2g43A TGEnWSoSIzjrUUhC3qqeag== 0000950123-95-003044.txt : 19951030 0000950123-95-003044.hdr.sgml : 19951030 ACCESSION NUMBER: 0000950123-95-003044 CONFORMED SUBMISSION TYPE: SC 13D/A PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 19951027 SROS: NASD GROUP MEMBERS: JOHNSON & JOHNSON DEVELOPMENT CORP. GROUP MEMBERS: JOHNSON & JOHNSON ET AL SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: AMYLIN PHARMACEUTICALS INC CENTRAL INDEX KEY: 0000881464 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 330266089 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13D/A SEC ACT: 1934 Act SEC FILE NUMBER: 005-42168 FILM NUMBER: 95584737 BUSINESS ADDRESS: STREET 1: 9373 TOWNE CENTRE DR CITY: SAN DIEGO STATE: CA ZIP: 92121 BUSINESS PHONE: 6195522200 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: JOHNSON & JOHNSON ET AL CENTRAL INDEX KEY: 0000200406 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 221024240 STATE OF INCORPORATION: NJ FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13D/A BUSINESS ADDRESS: STREET 1: ONE JOHNSON & JOHNSON PLZ CITY: NEW BRUNSWICK STATE: NJ ZIP: 08933 BUSINESS PHONE: 9085240400 SC 13D/A 1 AMENDMENT NO. 1 TO SCHEDULE 13D 1 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D UNDER THE SECURITIES EXCHANGE ACT OF 1934 (AMENDMENT NO. 1)* AMYLIN PHARMACEUTICALS, INC. ---------------------------- (Name of Issuer) COMMON STOCK, $.001 par value ------------------------------ (Title of Class of Securities) 032346108 -------------- (CUSIP Number) Blair M. Flicker, Esq. Johnson & Johnson One Johnson & Johnson Plaza New Brunswick, NJ 08933 (908) 524-2527 -------------------------------------------------------- (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications) October 17, 1995 ------------------ (Date of Event which Requires Filing of this Statement) If the filing person has previously filed a statement on Schedule 13G to report the acquisition which is the subject of this Schedule 13D, and is filing this schedule because of Rule 13d-1(b)(3) or (4), check the following box / /. Check the following box if a fee is being paid with the statement / /. (A fee is not required only if the reporting person: (1) has a previous statement on file reporting beneficial ownership of more than five percent of the class of securities described in Item 1; and (2) has filed no amendment subsequent thereto reporting beneficial ownership of five percent or less of such class.) (See Rule 13d-7.) NOTE: Six copies of this statement, including all exhibits, should be filed with the Commission. See Rule 13d-1(a) for other parties to whom copies are to be sent. *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page. The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). 2 SCHEDULE 13D CUSIP NO. 032346108 PAGE 2 OF 7 PAGES --------- ----- ---- - ------------------------------------------------------------------------------------------------------------------------------------ 1 NAME OF REPORTING PERSON S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON Johnson & Johnson 22-1024240 - ------------------------------------------------------------------------------------------------------------------------------------ 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (A) / / (B) / / - ------------------------------------------------------------------------------------------------------------------------------------ 3 SEC USE ONLY - ------------------------------------------------------------------------------------------------------------------------------------ 4 SOURCE OF FUNDS* - ------------------------------------------------------------------------------------------------------------------------------------ 5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e) / / - ------------------------------------------------------------------------------------------------------------------------------------ 6 CITIZENSHIP OR PLACE OF ORGANIZATION New Jersey - ------------------------------------------------------------------------------------------------------------------------------------ 7 SOLE VOTING POWER -0- NUMBER OF ------------------------------------------------------------------------------------------------------------ SHARES 8 SHARED VOTING POWER BENEFICIALLY OWNED BY EACH 1,955,407 REPORTING ------------------------------------------------------------------------------------------------------------ PERSON 9 SOLE DISPOSITIVE POWER WITH -0- ------------------------------------------------------------------------------------------------------------ 10 SHARED DISPOSITIVE POWER 1,955,407 - ------------------------------------------------------------------------------------------------------------------------------------ 11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 1,955,407 - ------------------------------------------------------------------------------------------------------------------------------------ 12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES* / / - ------------------------------------------------------------------------------------------------------------------------------------ 13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 6.99% - ------------------------------------------------------------------------------------------------------------------------------------ 14 TYPE OF REPORTING PERSON* CO - ------------------------------------------------------------------------------------------------------------------------------------
*SEE INSTRUCTIONS BEFORE FILLING OUT! INCLUDE BOTH SIDES OF THE COVER PAGE, RESPONSES TO ITEMS 1-7 (INCLUDING EXHIBITS) OF THE SCHEDULE, AND THE SIGNATURE ATTESTATION. 3 SCHEDULE 13D CUSIP NO. 032346108 PAGE 3 OF 7 PAGES --------- ----- ---- - ------------------------------------------------------------------------------------------------------------------------------------ 1 NAME OF REPORTING PERSON S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON Johnson & Johnson Development Corporation 22-2007317 - ------------------------------------------------------------------------------------------------------------------------------------ 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (A) / / (B) / / - ------------------------------------------------------------------------------------------------------------------------------------ 3 SEC USE ONLY - ------------------------------------------------------------------------------------------------------------------------------------ 4 SOURCE OF FUNDS* - ------------------------------------------------------------------------------------------------------------------------------------ 5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e) / / - ------------------------------------------------------------------------------------------------------------------------------------ 6 CITIZENSHIP OR PLACE OF ORGANIZATION New Jersey - ------------------------------------------------------------------------------------------------------------------------------------ 7 SOLE VOTING POWER -0- NUMBER OF ------------------------------------------------------------------------------------------------------------ SHARES 8 SHARED VOTING POWER BENEFICIALLY OWNED BY EACH 1,955,407 REPORTING ------------------------------------------------------------------------------------------------------------ PERSON 9 SOLE DISPOSITIVE POWER WITH -0- ------------------------------------------------------------------------------------------------------------ 10 SHARED DISPOSITIVE POWER 1,955,407 - ------------------------------------------------------------------------------------------------------------------------------------ 11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 1,955,407 - ------------------------------------------------------------------------------------------------------------------------------------ 12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES* / / - ------------------------------------------------------------------------------------------------------------------------------------ 13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 6.99% - ------------------------------------------------------------------------------------------------------------------------------------ 14 TYPE OF REPORTING PERSON* CO - ------------------------------------------------------------------------------------------------------------------------------------
*SEE INSTRUCTIONS BEFORE FILLING OUT! INCLUDE BOTH SIDES OF THE COVER PAGE, RESPONSES TO ITEMS 1-7 (INCLUDING EXHIBITS) OF THE SCHEDULE, AND THE SIGNATURE ATTESTATION. 4 Page 4 of 7 pages Items 3, 4 and 5 of the Statement on Schedule 13D filed pursuant to Rule 13d-1 of the Rules and Regulations under the Securities Exchange Act of 1934, as amended, by Johnson & Johnson, a New Jersey corporation ("J&J"), and Johnson & Johnson Development Corporation, a New Jersey corporation ("JJDC"), relating to the shares of Common Stock, $.001 par value (the "Common Stock") of Amylin Pharmaceuticals, Inc., are hereby amended as follows: 5 Page 5 of 7 pages Item 3. Source and Amount of Funds or Other Consideration: Item 3 is hereby amended and restated as follows: On June 20, 1995, JJDC purchased from Amylin Pharmaceuticals, Inc., a Delaware Corporation (the "Company") 724,638 shares of Common Stock of the Company for $5.0 million. On September 27, 1995, JJDC purchased from the Company 1,169,230 shares of Common Stock of the Company for $9.5 million. On October 17, 1995, JJDC purchased from the Company 61,539 shares of Common Stock of the Company for $0.5 million. No funds were borrowed to finance the purchases. Item 4. Purpose of Transaction: Item 4 is hereby amended and restated as follows: On June 20, 1995, the Company and Lifescan, Inc., a wholly-owned subsidiary of J&J, entered into a Collaboration Agreement to develop and commercialize the Company's lead drug candidate, pramlintide (the "Collaboration"). In conjunction with the Collaboration Agreement, the Company also entered into a Stock Purchase Agreement with JJDC and a Loan and Security Agreement with J&J. In accordance with the terms of the Stock Purchase Agreement, JJDC purchased 724,638 shares of Common Stock for $5.0 million. Subject to the terms of the Stock Purchase Agreement, the Company has the right to sell additional shares of Common Stock to JJDC in an aggregate amount of $10.0 million prior to the first milestone of the Collaboration. Pursuant to such right, on September 27, 1995, JJDC purchased 1,169,230 shares from the Company for $9.5 million and on October 17, 1995 purchased 61,539 shares from the Company for $0.5 million. Upon the achievement of certain additional milestones, the Company also has the right to sell additional shares of its Common Stock to JJDC for net proceeds of up to $30 million. 6 Page 6 of 7 pages Pursuant to the terms of the Loan and Security Agreement, the Company has agreed to issue to J&J warrants (the "Warrants") to purchase 50,000 shares of Common Stock, at an exercise price of $12.00 per share and with a ten-year exercise period, for each $1.0 million principal amount of each Development Loan (as defined in the Loan and Security Agreement) loaned to the Company thereunder. As of the October 5, 1995, no Development Loans had been made under the Loan and Security Agreement. Pursuant to the terms of the Stock Purchase Agreement, JJDC has agreed that, until June 2005, or sooner in the event that the Collaboration Agreement is terminated, it will not acquire any additional securities of the Company other than pursuant to the Stock Purchase Agreement or upon exercise of the Warrants. Such restriction shall terminate upon the occurrence of a change in control of the Company or certain other events, as described more fully in the Stock Purchase Agreement. JJDC has also agreed not to sell, transfer or dispose of any shares of Common Stock for certain time periods, as set forth more fully in the Stock Purchase Agreement. Item 5. Interest in Securities of the Issuer: Item 5 is hereby amended and restated as follows: As of October 26, 1995, J&J and JJDC each had beneficial ownership of an aggregate of 1,955,407 shares of Common Stock. Based upon the shares of Common Stock outstanding as of June 30, 1995, as reported in the Company's Amendment No. 1 on Form 10-Q/A for the quarter ended June 30, 1995, and the shares of Common Stock offered pursuant to the Company's Prospectus dated September 22, 1995, 1,955,407 shares constitute approximately 6.99% of the outstanding shares of Common Stock. 7 Page 7 of 7 pages SIGNATURES After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. JOHNSON & JOHNSON DEVELOPMENT CORPORATION By: /s/ B.M. Flicker ------------------- B.M. Flicker Secretary Date: October 26, 1995 JOHNSON & JOHNSON By: /s/ P.S. Galloway ------------------- P.S. Galloway Secretary Date: October 26, 1995 -----END PRIVACY-ENHANCED MESSAGE-----